CompletedNot Applicable

Artificial Intelligence to Improve Detection and Risk Stratification of Acute Pulmonary Embolism (AID-PE)

United Kingdom3,872 participantsStarted 2024-01-08

Plain-language summary

The goal of this exploratory observational study is to assess the feasibility and real-world clinical impact of implementing Artificial Intelligence (AI) software for the detection of acute Pulmonary Embolism (PE) in patients who undergo Computed Tomography Pulmonary Angiogram (CTPA). The main questions that this study aims to answer are: \[Question 1\] What is the real-world impact of AI on the clinical outcomes and decision making by radiologists and clinicians in the management of acute PE? \[Question 2\] Is AI software for the detection of acute PE acceptable to use in clinical practice and do they have a favourable impact on clinical workload? \[Question 3\] Is it cost-effective to implement AI software for the detection of acute PE in clinical practice? Patients having a CTPA for the detection of acute PE will have their imaging analysed by AI software in combination with a human radiologist. Researchers will aim to compare the clinical and radiology specific outcomes with a retrospective cohort of patients who have had standard routine radiology reporting.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients over 18 years of age * Patient requiring CTPA to exclude or diagnose acute PE Exclusion Criteria: * Patients under 18 years of age * Patients who have registered with the national opt-out scheme for research * CTPA performed for reasons other than acute PE * CTPA performed for acute PE but reported by external radiologists * Incomplete or discontinued CTPA scans * Insufficient quality CTPA to allow for analysis by a radiologist

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Proportion of patient decisions made in line with evidence based best practice guidelines after introducing AI technology within CTPA reporting

Timeframe: 12 months

Trial details

NCT IDNCT06093217

SponsorRoyal United Hospitals Bath NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-08

View on ClinicalTrials.gov More Pulmonary Embolism trials